57.17
price up icon1.74%   0.98
pre-market  Pre-mercato:  57.82   0.65   +1.14%
loading
Precedente Chiudi:
$56.19
Aprire:
$56.19
Volume 24 ore:
2.99M
Relative Volume:
1.51
Capitalizzazione di mercato:
$11.02B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
21.25
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
+5.60%
1M Prestazione:
+0.21%
6M Prestazione:
-14.02%
1 anno Prestazione:
-30.47%
Intervallo 1D:
Value
$56.19
$57.61
Intervallo di 1 settimana:
Value
$53.76
$57.61
Portata 52W:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
Nome
Biomarin Pharmaceutical Inc
Name
Telefono
(415) 506-6700
Name
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Name
Dipendente
3,040
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-29
Name
Ultimi documenti SEC
Name
BMRN's Discussions on Twitter

Confronta BMRN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
57.17 11.02B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-24 Aggiornamento Oppenheimer Perform → Outperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-10-30 Downgrade William Blair Outperform → Mkt Perform
2024-10-10 Ripresa Raymond James Outperform
2024-08-20 Aggiornamento Bernstein Mkt Perform → Outperform
2024-05-17 Downgrade Robert W. Baird Outperform → Neutral
2024-05-14 Iniziato Evercore ISI Outperform
2023-11-15 Iniziato Wells Fargo Overweight
2023-10-23 Aggiornamento Bernstein Underperform → Mkt Perform
2023-09-28 Iniziato Raymond James Mkt Perform
2023-09-18 Iniziato UBS Buy
2023-07-27 Iniziato Scotiabank Sector Perform
2023-07-05 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-06-14 Ripresa Credit Suisse Outperform
2023-03-21 Iniziato Bernstein Underperform
2023-02-22 Downgrade Oppenheimer Outperform → Perform
2023-02-21 Iniziato Citigroup Neutral
2023-01-30 Iniziato BMO Capital Markets Market Perform
2023-01-18 Iniziato Canaccord Genuity Hold
2022-10-31 Aggiornamento Oppenheimer Perform → Outperform
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-13 Ripresa Wedbush Neutral
2022-04-25 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-11-22 Aggiornamento William Blair Mkt Perform → Outperform
2021-10-07 Ripresa Jefferies Buy
2021-09-09 Aggiornamento Stifel Hold → Buy
2021-06-04 Ripresa Robert W. Baird Outperform
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-04 Ripresa Guggenheim Buy
2021-03-01 Aggiornamento Evercore ISI In-line → Outperform
2020-08-20 Downgrade Citigroup Buy → Neutral
2020-08-20 Downgrade William Blair Outperform → Mkt Perform
2020-08-19 Downgrade Evercore ISI Outperform → In-line
2020-08-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-08-19 Downgrade Stifel Buy → Hold
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-07-06 Reiterato Citigroup Buy
2020-01-28 Iniziato BMO Capital Markets Market Perform
2020-01-27 Iniziato BMO Capital Markets Market Perform
2020-01-24 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2019-11-27 Aggiornamento Barclays Equal Weight → Overweight
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-05-23 Ripresa Citigroup Buy
2019-04-09 Ripresa Raymond James Outperform
2019-01-02 Downgrade Raymond James Outperform → Mkt Perform
2018-12-14 Iniziato Wolfe Research Outperform
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-08-07 Reiterato Stifel Buy
2018-08-03 Reiterato Stifel Buy
Mostra tutto

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

pulisher
Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025
pulisher
Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025
pulisher
Jun 09, 2025

Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com

Jun 09, 2025
pulisher
Jun 05, 2025

Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool

Jun 05, 2025
pulisher
Jun 05, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Marin Awareness Walk Draws Over 100 Community Members - Patch

Jun 04, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans - Investing.com

Jun 02, 2025
pulisher
May 30, 2025

BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews

May 30, 2025
pulisher
May 30, 2025

The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN

May 29, 2025
pulisher
May 28, 2025

Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com

May 28, 2025
pulisher
May 28, 2025

Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 - Investing.com

May 27, 2025
pulisher
May 26, 2025

Phenylktonuria Treatment Market Overall Study Report - openPR.com

May 26, 2025
pulisher
May 26, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance

May 26, 2025
pulisher
May 25, 2025

BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com

May 25, 2025
pulisher
May 24, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN

May 24, 2025
pulisher
May 24, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 24, 2025
pulisher
May 23, 2025

Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media

May 23, 2025
pulisher
May 22, 2025

BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks

May 22, 2025
pulisher
May 22, 2025

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo

May 22, 2025
pulisher
May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025
pulisher
May 21, 2025

6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World

May 21, 2025
pulisher
May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025
pulisher
May 20, 2025

Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Is this European biotech’s moment? — a BioCentury podcast - biocentury.com

May 19, 2025
pulisher
May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025
pulisher
May 19, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 19, 2025
pulisher
May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

May 19, 2025
pulisher
May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025
pulisher
May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025

Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):